Trial reportSignal transduction and targeted therapy2026
Efficacy and safety of toripalimab in combination with cetuximab in patients with recurrent or metastatic head and neck squamous cell carcinoma (R/M HNSCC): a phase 1b/2 study.
Trial report in Signal transduction and targeted therapy, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT04856631 (A Phase Ib/II, Single-arm, Multi-center Clinical Study of Toripalimab Injection), which is not on this map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
A Phase Ib/II, Single-arm, Multi-center Clinical Study of Toripalimab Injection (JS001) + Cetuximab in Treatment of Advanced Head and Neck Squamous Cell Cancer
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
31 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
This open-label, multicenter, phase 1b/2 trial assessed the safety and efficacy of toripalimab plus cetuximab in patients with platinum-refractory (Cohort A) or previously untreated programmed cell death-ligand 1 (PD-L1)-positive (Cohort B) recurrent or metastatic head and neck squamous cell carcinoma (R/M HNSCC). Patients received toripalimab 240 mg intravenously (IV) every 3 weeks and cetuximab (400 mg/m² loading, then 250 mg/m² weekly maintenance). Primary endpoints were safety in phase 1b and objective response rate (ORR) as assessed by the Independent Review Committee (Cohort A) and investigator (Cohort B) in phase 2. Secondary efficacy endpoints included progression-free survival (PFS) and overall survival (OS). By October 25, 2024, 88 patients were enrolled (Cohort A: 45; cohort B: 43). In Cohort A, confirmed ORR was 60.0% (95% confidence interval [CI]: 44.3%, 74.3%), median PFS was 9.9 months (95% CI: 4.2, 19.4), and median OS was 14.1 months (95% CI: 8.5, 17.7). PD-L1-positive (combined positive score [CPS] ≥1) patients appeared to benefit more than PD-L1-negative (CPS < 1) patients (ORR: 64.5% vs. 40.0%, median PFS: 10.4 vs. 4.0 months, median OS: 15.4 vs. 13.3 months). In Cohort B, confirmed ORR was 44.2% (95% CI: 29.1%, 60.1%), median PFS was 8.2 months (95% CI: 4.2, 17.1), and median OS was 18.1 months (95% CI: 10.6, inestimable). Grade ≥3 treatment-emergent adverse events occurred in 53.3% (Cohort A) and 51.2% (Cohort B) of the patients in phase 2. No novel safety signals were identified. Toripalimab combined with cetuximab demonstrated manageable safety and promising efficacy for R/M HNSCC, warranting further investigation. Clinical trial number: NCT04856631.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.